Research chemicalResearch chemicalPsychedelicLysergamide

CE-LAD

Also known as CE-LAD · CEP-LAD

Written by enwyReviewed 4 Aug 20261 sources0 comments

CE-LAD is a novel lysergamide research chemical, a substituted LAD-series analogue of LSD sold on blotter. It is very new and poorly characterised, reported to produce LSD-like psychedelic effects. Essentially all information comes from a small number of user reports.

01 Overview

CE-LAD belongs to the LAD (6-allyl-nor-LSD) family of lysergamide research chemicals, carrying a substituent that distinguishes it from AL-LAD and related compounds. It is among the newer entries to the grey-market lysergamide scene and is distributed almost exclusively on micrograms-dosed blotter.

Reported effects are broadly LSD-like: visual geometry, mood elevation, cognitive alteration and stimulation, with anecdotal descriptions of duration and potency still sparse and inconsistent. There is no clinical or preclinical characterisation to speak of, so any statement about its effects, potency or safety is provisional. As with all lysergamides, the main risks are psychological rather than physiological.

02 Mechanism

Presumed agonist at serotonin 5-HT2A receptors, the mechanism shared by lysergamide psychedelics.

03 Dosing

Tier	Dose	Route	Notes
Light	50–100 mcg	Sublingual	Potency poorly established; start low.
Common	100–200 mcg	Sublingual	Doses are provisional given minimal data.

04 Effects

Effect	Magnitude	Evidence
Visual alterationGeometric visuals and perceptual enhancement, reported as LSD-like.	Dose-dependent	Anecdotal
Mood elevationEuphoria and emotional openness.		Anecdotal
Cognitive alterationAltered thought and time perception.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Anxiety and difficult experiencesAnxiety or challenging experiences, especially given uncertain potency.	Moderate	Dose- and set-dependent	Anecdotal
Cardiovascular stimulationIncreased heart rate and blood pressure.	Mild	Common	Anecdotal
Unknown long-term safetyAs a very new compound, its long-term safety and toxicology are entirely uncharacterised.	Moderate	Unknown	Unconfirmed

06 Legal status

United States

Possible analogue of Schedule I LSD

as of Jan 2026

United Kingdom

Class A (lysergamide)

as of Jan 2026

07 References

Emerging LAD-series lysergamidesNPS monitoring / analytical literature

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.